UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043756
Receipt number R000047581
Scientific Title Nationwide evaluation of Streptococcus pneumoniae serotype distribution among adults with community-onset pneumonia in Japan
Date of disclosure of the study information 2021/03/26
Last modified on 2021/03/26 17:01:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Nationwide evaluation of Streptococcus pneumoniae serotype distribution among adults with community-onset pneumonia in Japan

Acronym

Nationwide evaluation of Streptococcus pneumoniae serotype distribution among adults with community-onset pneumonia in Japan

Scientific Title

Nationwide evaluation of Streptococcus pneumoniae serotype distribution among adults with community-onset pneumonia in Japan

Scientific Title:Acronym

Nationwide evaluation of Streptococcus pneumoniae serotype distribution among adults with community-onset pneumonia in Japan

Region

Japan


Condition

Condition

Community Onset pneumonia; Community acquired and Healthcare associated pneumonia

Classification by specialty

Medicine in general Pneumology Infectious disease
Geriatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

1. To establish the serotype distribution of S.pneumoniae isolates obtained from adult pneumonia patients
2. To describe the clinical characteristics of community-onset pneumonia associated with individual serotypes of S.pneumoniae
3. To advocate a precise pneumococcal vaccine policy

Basic objectives2

Others

Basic objectives -Others

investigation

Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To establish the serotype distribution of S.pneumoniae isolates obtained from adult pneumonia patients in Japan.

Key secondary outcomes

1. To describe the clinical characteristics of community-onset pneumonia associated with individual serotypes of S.pneumoniae
2. To establish antibiotic susceptibility patterns and MLST profiles for S.pneumoniae isolates obtained from adult patients with COP


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Adults patients with community-onset pneumoniae (having symptoms compatible with pneumonia (i.e. fever, hypothermia, chills or rigors, cough, sputum, pleuritic chest pain, dyspnea, tachypnea, or malaise) and with new pulmonary infiltrates on chest X-ray or computed tomography (CT) scan (consistent with pneumonia.)
2. With isolated S.pneumoniae from respiratory specimen, blood, or pleural fluid

Key exclusion criteria

1. A case diagnosed with pneumonia 48 hours or more after admission to the hospital
2. Patients who previously included in the study within past 30 days
3. Patients who declined to participate in hospital research via opt-out process

Target sample size

3000


Research contact person

Name of lead principal investigator

1st name Konosuke
Middle name
Last name Morimoto

Organization

Institute of Tropical Medicine, Nagasaki University

Division name

Department of Respiratory Infections

Zip code

852-8523

Address

Sakamoto, Nagasaki city, Nagasaki, 852-8523,Japan

TEL

095-819-7842

Email

komorimo@nagasaki-u.ac.jp


Public contact

Name of contact person

1st name Haruka,Konosuke
Middle name
Last name Maeda, Morimoto

Organization

Institute of Tropical Medicine, Nagasaki University

Division name

Department of Respiratory Infections

Zip code

852-8523

Address

Sakamoto, Nagasaki city, Nagasaki, 852-8523,Japan

TEL

095-819-7842

Homepage URL


Email

mharuka@nagasaki-u.ac.jp


Sponsor or person

Institute

Institute of Tropical Medicine, Nagasaki University

Institute

Department

Personal name



Funding Source

Organization

Pfizer Inc.

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board at Institutional of Tropical Medicine at Nagasaki University

Address

1-12-4,Sakamoto, Nagasaki city, Nagasaki, 852-8523,Japan

Tel

095-819-7803

Email

soum-nekken@ml.nagasaki-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

京都大学(京都)、近森病院(高知県)、他約20施設


Other administrative information

Date of disclosure of the study information

2021 Year 03 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2020 Year 10 Month 14 Day

Date of IRB

2019 Year 12 Month 11 Day

Anticipated trial start date

2020 Year 11 Month 01 Day

Last follow-up date

2023 Year 11 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

The anonymized data of pneumococcal strain and patient's information including age, sex, underlying diseases, vaccination history, the severity of pneumonia, and hospital death or not, are used.


Management information

Registered date

2021 Year 03 Month 26 Day

Last modified on

2021 Year 03 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047581


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name